Enlivex Ltd. (ENLV)
0.2618
-0.02
(-5.49%)
USD |
NASDAQ |
Oct 09, 14:29
Enlivex EPS Diluted (Quarterly) : 97.84 for June 30, 2026
EPS Diluted (Quarterly) Chart
Historical EPS Diluted (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 97.84 |
| December 31, 2025 | 386.85 |
| September 30, 2025 | -1.376 |
| June 30, 2025 | -1.174 |
| March 31, 2025 | -2.179 |
| December 31, 2024 | -3.283 |
| September 30, 2024 | -0.1223 |
| June 30, 2024 | -0.1584 |
| March 31, 2024 | -0.2211 |
| December 31, 2023 | -0.489 |
| September 30, 2023 | -0.3206 |
| June 30, 2023 | -0.3655 |
| March 31, 2023 | -0.3898 |
| December 31, 2022 | -0.3902 |
| September 30, 2022 | -0.3117 |
| June 30, 2022 | -0.5395 |
| March 31, 2022 | -0.4478 |
| December 31, 2021 | -0.2583 |
| September 30, 2021 | -0.187 |
| June 30, 2021 | -0.1698 |
| March 31, 2021 | -0.1942 |
| December 31, 2020 | -0.4311 |
| September 30, 2020 | -0.1578 |
| June 30, 2020 | -0.2262 |
| March 31, 2020 | -0.0697 |
| Date | Value |
|---|---|
| December 31, 2019 | -0.2774 |
| September 30, 2019 | -0.2342 |
| June 30, 2019 | -0.1445 |
| March 31, 2019 | -0.6891 |
| December 31, 2018 | 0.00 |
| September 30, 2018 | 0.00 |
| June 30, 2018 | 0.00 |
| March 31, 2018 | 0.00 |
| December 31, 2017 | -1.36 |
| September 30, 2017 | -2.56 |
| June 30, 2017 | -4.00 |
| March 31, 2017 | -6.40 |
| December 31, 2016 | -7.60 |
| September 30, 2016 | -11.20 |
| June 30, 2016 | -8.80 |
| March 31, 2016 | -12.80 |
| December 31, 2015 | -13.60 |
| September 30, 2015 | -10.00 |
| June 30, 2015 | -10.40 |
| March 31, 2015 | -9.20 |
| December 31, 2014 | -8.80 |
| September 30, 2014 | -6.40 |
| June 30, 2014 | -4.00 |
| March 31, 2014 | 0.00 |
| December 31, 2013 | -3.20 |
EPS Diluted (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
EPS Diluted (Quarterly) Benchmarks
| Polyrizon Ltd. | -- |
| NovelStem International Corp. | -0.0017 |
| Brainstorm Cell Therapeutics, Inc. | -0.3494 |
| Summit Therapeutics, Inc. | -0.2772 |
| PeptiDream Inc. | -0.0559 |
EPS Diluted (Quarterly) Related Metrics
| Net Income (Quarterly) | 1.892B |
| Total Expenses (Quarterly) | -1.892B |
| Enterprise Value | 16.58M |
| Earnings Yield | 184.2K% |
| Normalized Earnings Yield | 14198.74 |